ImmunityBio and NantKwest
Broad Clinical-Stage Immunotherapy Platforms
NK & T Cell
We established ImmunityBio to advance the next generation of immunotherapies and to address serious unmet needs within oncology and infectious diseases. Our platform is designed to overcome limitations of the existing therapeutic paradigm based on T cell-based immunotherapies, such as checkpoint inhibitors and chimeric antigen receptor T cells, or CAR-T cells.
Fundamentally, our platform promotes innate and adaptive immune responses by activating cytokines, natural killer, or NK, cells, T cells and tumoricidal macrophages, and seeks to establish “immunological memory” to support longer-term protection against disease. We believe our novel approach significantly improves upon standard immunotherapies to induce more rapid, robust and durable clinical benefit.
Our Clinical Stage Platforms
(1) Antibody fusion proteins which activate NK, T, and memory T cells;
(2) Albumin-based tumor microenvironment immune modulators; and
(3) Second generation adenovirus (hAd5) and yeast vectors to activate dendritic cells and induce long-term T cell memory.
fast track &
NantKwest, ImmunityBio Announce Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Trials
Pivotal QUILT 88 trial based on combination immunotherapy of “Cancer Moonshot” strategy; early indications of increased survival rate for pancreatic cancer patients with no other approved treatment...
NantKwest Executive Chairman Dr. Patrick Soon-Shiong to Present at 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021
EL SEGUNDO, Calif., January 6, 2021 — NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that Dr. Patrick Soon-Shiong M.D., Executive...
Detailed computer modeling, completed in partnership with Microsoft, explains virulence of COVID-19 and provides key information that may lead to a better understanding of the multiple mutations...